Sociedade Pernambucana de Combate ao Câncer

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- The energy-based non-invasive medical aesthetic treatment system market is forecasted to grow by USD 1,841.74 million from 2022 to 2027. Moreover, the growth momentum will accelerate at a CAGR of 11.11% during the forecast period, according to Technavio. AbbVie Inc., Alma Lasers GmbH, AngioDynamics Inc., Bausch Health Co Inc., Boston Scientific Corp., Candela Corp, Cutera Inc., Cynosure LLC, El.En. Spa., Galderma SA, Hologic Inc., INDIBA SA., Lumenis Be Ltd, Mentor Plastic Surgery., Merz Pharma GmbH and Co KGaA, Prollenium Medical Technologies Inc., Sciton Inc., Suneva Medical, and Johnson and Johnson are some of the major market participants. To know about the vendor offerings, request a sample report . Continue Reading Technavio has announced its latest market research report titled Global Energy-based Non-invasive Medical Aesthetic Treatment System Market 2023-2027 The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies, growth strategies, product innovations, new product launches, investments, growth in market share, among others - Buy the Report Energy-based non-invasive medical aesthetic treatment system market 2023-2027: Scope The energy-based non-invasive medical aesthetic treatment system market report also covers the following areas: Porter's five forces analysis Customer landscape Market trends Energy-based non-invasive medical aesthetic treatment system market 2023-2027: Drivers and challenges The growing awareness about the availability of energy-based non-invasive medical aesthetic treatment systems is driving the market's growth. New vendors are conducting various events and advertising their products to increase awareness about their products. Moreover, new and improved devices are being launched in the market due to advances in technology. For instance, Alma Lasers has launched Alma Care, a marketing package that provides clinical training, flexible financing options, marketing and media resources, and an extended warranty. Such initiatives will drive the global energy-based non-invasive medical aesthetic treatment systems market during the forecast period. The need for significant investments to offer energy-based non-invasive medical aesthetic treatment is challenging the market's growth. Manufacturers of these systems must invest heavily in research and development to develop advanced systems with technologies such as ultrasound, laser, and RF, which increases their costs. Old systems have to be replaced with the latest systems, which are expensive. The cost to maintain advanced energy-based non-invasive medical aesthetic treatment centers is also high. These factors may impede the growth of the market during the forecast period. To know about other drivers and challenges - Download a sample now! Energy-based non-invasive medical aesthetic treatment system market 2023-2027: Segmentation analysis Application outlook Skin rejuvenation Vaginal rejuvenation Hair Removal Leg vein treatment Others End-user outlook Medspa Hospitals and surgery centers HCP owned clinics Traditional spas Region outlook North America The US Canada Europe The UK Germany France Rest of Europe APAC China India Rest of World Brazil Argentina Rest of the Middle East & Africa Energy-based non-invasive medical aesthetic treatment system market 2023-2027: Segmentation highlights The energy-based non-invasive medical aesthetic treatment system market share growth by the skin rejuvenation segment will be significant. The growth of the segment will be driven by factors such as the increasing demand for anti-aging treatments. The demand for energy-based non-invasive medical aesthetic treatment systems for skin rejuvenation is increasing due to the growing awareness about the availability of advanced non-surgical anti-aging procedures. The growth of the segment is also driven by the economic growth of several countries, which has increased the disposable incomes of people and enhanced the standards of living. The growth of the geriatric population has also increased the demand for non-invasive treatments. North America is estimated to account for 46% of the growth of the global market during the forecast period. The market in the region will grow significantly due to high awareness and the increasing adoption of energy-based non-invasive medical aesthetic treatments. People from different parts of the world travel to North America due to the availability of advanced healthcare infrastructure and experienced HCPs. Thus, the availability of advanced diagnostic techniques and favorable reimbursements will drive the growth of the market during the forecast period. Energy-based non-invasive medical aesthetic treatment system market 2023-2027: Key Highlights What are the key data covered in this energy-based non-invasive medical aesthetic treatment system market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the energy-based non-invasive medical aesthetic treatment system market between 2023 and 2027 Precise estimation of the energy-based non-invasive medical aesthetic treatment system market size and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the industry across North America, Europe, Asia, and Rest of World (ROW) Thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of energy-based non-invasive medical aesthetic treatment system market vendors Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports: The energy-based aesthetic devices market is estimated to grow at a CAGR of 8.5% between 2022 and 2027. The size of the market is forecasted to increase by USD 1,752 million. This report extensively covers market segmentation by end-user (medspa, hospital or surgery center, HPC-owned clinic, and traditional spa), product (laser, light, ultrasound, and radiofrequency), and geography (North America, APAC, Europe, and Rest of World (ROW)). The non-invasive intracranial pressure monitoring devices market size is expected to increase by USD 125.89 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.02%. This report extensively covers market segmentation by application (traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, meningitis, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). Browse for Technavio's health care market reports Table of contents: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Application Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global energy-based non-invasive medical aesthetic treatment system market 2017 - 2021 Exhibit 18: Historic Market Size – Data table on global energy-based non-invasive medical aesthetic treatment system market 2017 - 2021 ($ million) 4.2 Application Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ million) 4.3 End-user Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Application 6.1 Market segments Exhibit 30: Chart on Application - Market share 2022-2027 (%) Exhibit 31: Data Table on Application - Market share 2022-2027 (%) 6.2 Comparison by Application Exhibit 32: Chart on Comparison by Application Exhibit 33: Data Table on Comparison by Application 6.3 Skin rejuvenation - Market size and forecast 2022-2027 Exhibit 34: Chart on Skin rejuvenation - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Skin rejuvenation - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Skin rejuvenation - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Skin rejuvenation - Year-over-year growth 2022-2027 (%) 6.4 Vaginal rejuvenation - Market size and forecast 2022-2027 Exhibit 38: Chart on Vaginal rejuvenation - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Vaginal rejuvenation - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Vaginal rejuvenation - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Vaginal rejuvenation - Year-over-year growth 2022-2027 (%) 6.5 Hair removal - Market size and forecast 2022-2027 Exhibit 42: Chart on Hair removal - Market size and forecast 2022-2027 ($ million) Exhibit 43: Data Table on Hair removal - Market size and forecast 2022-2027 ($ million) Exhibit 44: Chart on Hair removal - Year-over-year growth 2022-2027 (%) Exhibit 45: Data Table on Hair removal - Year-over-year growth 2022-2027 (%) 6.6 Leg vein treatment - Market size and forecast 2022-2027 Exhibit 46: Chart on Leg vein treatment - Market size and forecast 2022-2027 ($ million) Exhibit 47: Data Table on Leg vein treatment - Market size and forecast 2022-2027 ($ million) Exhibit 48: Chart on Leg vein treatment - Year-over-year growth 2022-2027 (%) Exhibit 49: Data Table on Leg vein treatment - Year-over-year growth 2022-2027 (%) 6.7 Others - Market size and forecast 2022-2027 Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%) 6.8 Market opportunity by Application Exhibit 54: Market opportunity by Application ($ million) 7 Market Segmentation by End-user 7.1 Market segments Exhibit 55: Chart on End-user - Market share 2022-2027 (%) Exhibit 56: Data Table on End-user - Market share 2022-2027 (%) 7.2 Comparison by End-user Exhibit 57: Chart on Comparison by End-user Exhibit 58: Data Table on Comparison by End-user 7.3 Medspa - Market size and forecast 2022-2027 Exhibit 59: Chart on Medspa - Market size and forecast 2022-2027 ($ million) Exhibit 60: Data Table on Medspa - Market size and forecast 2022-2027 ($ million) Exhibit 61: Chart on Medspa - Year-over-year growth 2022-2027 (%) Exhibit 62: Data Table on Medspa - Year-over-year growth 2022-2027 (%) 7.4 Hospitals and surgery center - Market size and forecast 2022-2027 Exhibit 63: Chart on Hospitals and surgery center - Market size and forecast 2022-2027 ($ million) Exhibit 64: Data Table on Hospitals and surgery center - Market size and forecast 2022-2027 ($ million) Exhibit 65: Chart on Hospitals and surgery center - Year-over-year growth 2022-2027 (%) Exhibit 66: Data Table on Hospitals and surgery center - Year-over-year growth 2022-2027 (%) 7.5 HCP owned clinic - Market size and forecast 2022-2027 Exhibit 67: Chart on HCP owned clinic - Market size and forecast 2022-2027 ($ million) Exhibit 68: Data Table on HCP owned clinic - Market size and forecast 2022-2027 ($ million) Exhibit 69: Chart on HCP owned clinic - Year-over-year growth 2022-2027 (%) Exhibit 70: Data Table on HCP owned clinic - Year-over-year growth 2022-2027 (%) 7.6 Traditional spa - Market size and forecast 2022-2027 Exhibit 71: Chart on Traditional spa - Market size and forecast 2022-2027 ($ million) Exhibit 72: Data Table on Traditional spa - Market size and forecast 2022-2027 ($ million) Exhibit 73: Chart on Traditional spa - Year-over-year growth 2022-2027 (%) Exhibit 74: Data Table on Traditional spa - Year-over-year growth 2022-2027 (%) 7.7 Market opportunity by End-user Exhibit 75: Market opportunity by End-user ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 76: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 77: Chart on Market share by geography 2022-2027 (%) Exhibit 78: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 79: Chart on Geographic comparison Exhibit 80: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 81: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 82: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 83: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 85: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 86: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 87: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 APAC - Market size and forecast 2022-2027 Exhibit 89: Chart on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 90: Data Table on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 91: Chart on APAC - Year-over-year growth 2022-2027 (%) Exhibit 92: Data Table on APAC - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 93: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 94: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 95: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 Germany - Market size and forecast 2022-2027 Exhibit 101: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 102: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 103: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 104: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.9 Japan - Market size and forecast 2022-2027 Exhibit 105: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 106: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 107: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 108: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.10 UK - Market size and forecast 2022-2027 Exhibit 109: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 110: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 111: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 112: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.11 China - Market size and forecast 2022-2027 Exhibit 113: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 114: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 115: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 116: Data Table on China - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 117: Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 118: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 119: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 120: Overview on factors of disruption 11.4 Industry risks Exhibit 121: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 122: Vendors covered 12.2 Market positioning of vendors Exhibit 123: Matrix on vendor position and classification 12.3 Alma Lasers GmbH Exhibit 124: Alma Lasers GmbH - Overview Exhibit 125: Alma Lasers GmbH - Product / Service Exhibit 126: Alma Lasers GmbH - Key offerings 12.4 Bausch Health Co Inc. Exhibit 127: Bausch Health Co Inc. - Overview Exhibit 128: Bausch Health Co Inc. - Business segments Exhibit 129: Bausch Health Co Inc. - Key news Exhibit 130: Bausch Health Co Inc. - Key offerings Exhibit 131: Bausch Health Co Inc. - Segment focus 12.5 Boston Scientific Corp. Exhibit 132: Boston Scientific Corp. - Overview Exhibit 133: Boston Scientific Corp. - Business segments Exhibit 134: Boston Scientific Corp. - Key news Exhibit 135: Boston Scientific Corp. - Key offerings Exhibit 136: Boston Scientific Corp. - Segment focus 12.6 Candela Corp Exhibit 137: Candela Corp - Overview Exhibit 138: Candela Corp - Product / Service Exhibit 139: Candela Corp - Key offerings 12.7 Cutera Inc. Exhibit 140: Cutera Inc. - Overview Exhibit 141: Cutera Inc. - Product / Service Exhibit 142: Cutera Inc. - Key offerings 12.8 Cynosure LLC Exhibit 143: Cynosure LLC - Overview Exhibit 144: Cynosure LLC - Product / Service Exhibit 145: Cynosure LLC - Key offerings 12.9 El.En. Spa. Exhibit 146: El.En. Spa. - Overview Exhibit 147: El.En. Spa. - Business segments Exhibit 148: El.En. Spa. - Key offerings Exhibit 149: El.En. Spa. - Segment focus 12.10 Hologic Inc. Exhibit 150: Hologic Inc. - Overview Exhibit 151: Hologic Inc. - Business segments Exhibit 152: Hologic Inc. - Key news Exhibit 153: Hologic Inc. - Key offerings Exhibit 154: Hologic Inc. - Segment focus 12.11 INDIBA SA. Exhibit 155: INDIBA SA. - Overview Exhibit 156: INDIBA SA. - Product / Service Exhibit 157: INDIBA SA. - Key offerings 12.12 Johnson and Johnson Exhibit 158: Johnson and Johnson - Overview Exhibit 159: Johnson and Johnson - Business segments Exhibit 160: Johnson and Johnson - Key news Exhibit 161: Johnson and Johnson - Key offerings Exhibit 162: Johnson and Johnson - Segment focus 12.13 Lumenis Be Ltd Exhibit 163: Lumenis Be Ltd - Overview Exhibit 164: Lumenis Be Ltd - Product / Service Exhibit 165: Lumenis Be Ltd - Key offerings 12.14 Merz Pharma GmbH and Co KGaA Exhibit 166: Merz Pharma GmbH and Co KGaA - Overview Exhibit 167: Merz Pharma GmbH and Co KGaA - Product / Service Exhibit 168: Merz Pharma GmbH and Co KGaA - Key offerings 12.15 Prollenium Medical Technologies Inc. Exhibit 169: Prollenium Medical Technologies Inc. - Overview Exhibit 170: Prollenium Medical Technologies Inc. - Business segments Exhibit 171: Prollenium Medical Technologies Inc. - Key offerings Exhibit 172: Prollenium Medical Technologies Inc. - Segment focus 12.16 Sciton Inc. Exhibit 173: Sciton Inc. - Overview Exhibit 174: Sciton Inc. - Product / Service Exhibit 175: Sciton Inc. - Key offerings 12.17 Suneva Medical Exhibit 176: Suneva Medical - Overview Exhibit 177: Suneva Medical - Product / Service Exhibit 178: Suneva Medical - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 179: Inclusions checklist Exhibit 180: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 181: Currency conversion rates for US$ 13.4 Research methodology Exhibit 182: Research methodology Exhibit 183: Validation techniques employed for market sizing Exhibit 184: Information sources 13.5 List of abbreviations Exhibit 185: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports, covering 800 technologies spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

REXBURG, Idaho, Dec. 13, 2022 /PRNewswire/ -- HCP, the leading provider of experience management, training, and reputation management, has launched a full suite of OASIS-E training courses to support agencies in navigating regulatory updates and meeting compliance requirements. Authored by HCP Nurse Educator, Maria Wharton RN, MSN, COS-C, the OASIS-D1 to OASIS-E series includes the following online education: Continue Reading HCP has launched a full suite of OASIS-E training courses to help agencies navigate regulatory updates. Tweet this Have you heard? The new OASIS-E assessment tool debuts January 1st, 2023—and HCP Training has got you covered with an entire suite of courses to help you meet your agency's learning needs. OASIS-D1 to OASIS-E Updates: A course for experienced clinicians with a focus on the new and updated OASIS items. OASIS-E Basics: This course digs deeper into the reasons behind the assessment tool itself and why it relates to identifying and improving quality indicators across the home health industry. OASIS-E Section by Section: An interactive lecture-based suite of courses that addresses every section of the OASIS assessment. Home health administrators and clinicians will enjoy in-depth instruction from Wendie Colvin RN, MSN, an HCP nurse educator, author, and OASIS facilitator. HCP's OASIS-E series offers the opportunity to identify available resources for completing assessments, understand the reasons behind the CMS changes, adapt to complete thorough, accurate patient assessments, and utilize the OASIS-E assessment to drive high quality patient care. "We're thrilled to be able to offer such a comprehensive OASIS-E series through HCP Training," said Wendie Colvin, Senior Clinical Content Writer at HCP. "The HCP Content Team worked very hard to take each section of OASIS-E and break it down into easily digestible course offerings for our learners. With the significant OASIS changes that are taking place on January 1st, 2023, this series will help agencies become more confident and prepared going into the new year." HCP has also created a free OASIS-D1 to OASIS-E Crosswalk, providing a concise reference of each OASIS-E assessment category and code and noting which items have been removed, updated, or newly created. Download the free resource here. About HCP HCP leads the home-based care industry in experience management, training, and reputation management. Through its Care Intelligence Platform, HCP empowers providers in home care, home health, and hospice to attract and retain employees during workforce shortages. HCP also conducts the annual Benchmarking Report, the most comprehensive survey of providers in North America, and administers Best of Home Care awards to agencies that achieve best-in-class satisfaction scores. For more information, visit . Media Contact Megan Kujawa – [email protected] SOURCE Home Care Pulse

Thirty-six abstracts underscore AbbVie's commitment to advancing research to help more people living with rheumatic diseases Additional analysis of long-term safety data for RINVOQ® (upadacitinib) and SKYRIZI® (risankizumab) NORTH CHICAGO, Ill., Nov. 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology's annual meeting (ACR Convergence 2022) taking place November 10-14 in Philadelphia, PA, as well as virtually. "AbbVie has a rich legacy spanning more than two decades where we have consistently worked to deliver new insights and innovation in rheumatology," said Celine Goldberger, M.D., Ph.D., vice president, head of U.S. medical affairs, AbbVie. "Data being presented at this year's ACR meeting further reflect AbbVie's commitment to advancing our portfolio of medicine to help more people living with chronic and debilitating conditions achieve meaningful disease control." Data to be presented includes: Data on rates of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) in the RA, PsA and AS clinical trial programs of upadacitinib.1 Real-world data evaluating the impact of a second-line therapeutic product on disease control in patients living with psoriatic arthritis.2 Several poster presentations on data from the KEEPsAKE clinical trials evaluating risankizumab in psoriatic arthritis including long-term data across specific sub-groups, and SELECT clinical trials evaluating upadacitinib in psoriatic arthritis, rheumatoid arthritis and axial spondyloarthritis.3-7 Select AbbVie abstracts presented at ACR 2022 are outlined below. SKYRIZI (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of SKYRIZI globally. The full list of all 36 abstracts and ACR Convergence 2022 scientific program can be found here. About RINVOQ® (upadacitinib) in the United States Discovered and developed by AbbVie scientists, RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.8 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known. In the U.S., RINVOQ 15 mg is approved for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers; adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers; adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers and adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.8 RINVOQ 45 mg is approved for use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers as an induction therapy once daily for 8 weeks. The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily. A dosage of 30 mg once daily may be considered for patients with refractory, severe or extensive disease. Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose. Use the lowest effective dosage needed to maintain response. RINVOQ 15 mg once daily can also be initiated in adults and children 12 years of age and older weighing at least 40 kg with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics or when use of those therapies is inadvisable. In these children and adults less than 65 years of age who do not achieve an adequate response, the dose may be increased to 30 mg once daily. Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.9-16 RINVOQ® (upadacitinib) U.S. Use and Important Safety Information8 USES RINVOQ is a prescription medicine used to treat: Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis. Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis. IMPORTANT SAFETY INFORMATION What is the most important information I should know about RINVOQ? RINVOQ may cause serious side effects, including: Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster). Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor. Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen. Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker. Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor. Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away. Tears in the stomach or intestines and changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results. Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients. What should I tell my HCP BEFORE starting RINVOQ? Tell your HCP if you: Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as: Fever, sweating, or chills Shortness of breath Warm, red, or painful skin or sores on your body Muscle aches Feeling tired Blood in phlegm Diarrhea or stomach pain Cough Weight loss Burning when urinating or urinating more often than normal Have TB or have been in close contact with someone with TB. Are a current or past smoker. Have had a heart attack, other heart problems, or stroke. Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines. Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system. Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP. Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines. Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose. Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects. Especially tell your HCP if you take: Medicines for fungal or bacterial infections Rifampicin or phenytoin Medicines that affect your immune system If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist. What should I avoid while taking RINVOQ? Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects. What should I do or tell my HCP AFTER starting RINVOQ? Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw Pain or discomfort in your arms, back, neck, jaw, or stomach Shortness of breath with or without chest discomfort Breaking out in a cold sweat Nausea or vomiting Feeling lightheaded Weakness in one part or on one side of your body Slurred speech Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including: Swelling Pain or tenderness in one or both legs Sudden unexplained chest or upper back pain Shortness of breath or difficulty breathing Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits. What are other possible side effects of RINVOQ? Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, and increased liver enzyme levels. A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ. These are not all the possible side effects of RINVOQ. How should I take RINVOQ? RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. This is the most important information to know about RINVOQ. For more information, talk to your HCP. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. Please click here for the Full Prescribing Information and Medication Guide. Globally, prescribing information varies; refer to the individual country product label for complete information. About SKYRIZI® (risankizumab-rzaa) in the United States17 SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). SKYRIZI U.S. Uses and Important Safety Information17 SKYRIZI is a prescription medicine used to treat adults with: moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). active psoriatic arthritis (PsA). moderate to severe Crohn's disease. IMPORTANT SAFETY INFORMATION What is the most important information I should know about SKYRIZI® ( risankizumab-rzaa)? SKYRIZI is a prescription medicine that may cause serious side effects, including: Serious allergic reactions: Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: fainting, dizziness, feeling lightheaded (low blood pressure) swelling of your face, eyelids, lips, mouth, tongue, or throat trouble breathing or throat tightness chest tightness skin rash, hives itching Infections: SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your mucus (phlegm) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients. Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you: have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine. are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk. become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of SKYRIZI? SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?" Liver problems in Crohn's disease: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and up to 12 weeks of treatment and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine. The most common side effects of SKYRIZI in people treated for Crohn's disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection. The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections. These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects. Use SKYRIZI exactly as your healthcare provider tells you to use it. SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector. This is the most important information to know about SKYRIZI. For more information, talk to your HCP. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. Please click here for Full Prescribing Information and Medication Guide for SKYRIZI. Globally, prescribing information varies; refer to the individual country product label for complete information. About AbbVie in Rheumatology For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Anchored by a longstanding commitment to discovering and delivering transformative therapies, we pursue cutting-edge science that improves our understanding of promising new pathways and targets, ultimately helping more people living with rheumatic diseases reach their treatment goals. For more information, visit AbbVie in rheumatology. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women's health, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. US-MULT-221303 References: Charles-Schoeman C, Choy E, McInnes I, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel A, Palac H, Suboticki J, Curtis J. MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). . Accessed November 8, 2022. Ogdie A, McLean R, Blachley T, Middaugh N, Mittal M, Clewell J, Ciecinski S, Mease P. The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). . Accessed November 8, 2022. Kwatra S, Khattri S, Amin A, Photowala H, Liu R, Padilla B, Kaplan B, McGonagle D. Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). . Accessed November 8, 2022. Erik L, Papp K, White D, Asnal C, Lu W, Soliman A, Padilla B, Chen M, Ostor A. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). . Accessed November 8, 2022. Merola J, Callis-Duffin K, Padilla B, Yue C, Photowala H, Kaplan B, McInnes I. Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). . Accessed November 8, 2022. Merola J, McInnes I, Kavanaugh A, Nash P, Xue Z, Stakias V, Eldred A, Ciecinski S, Douglas K, Coates L. Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). . Accessed November 8, 2022. Ogdie A, Merola J, Ranza R, Soliman A, Mittal M, Padilla B, Ciecinski S, Nakasato P, Gossec L. Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). . Accessed November 8, 2022. RINVOQ® (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc. A study comparing upadacitinib (ABT-494) to placebo and to adalimumab in adults with rheumatoid arthritis who are on a stable dose of methotrexate and who have an inadequate response to methotrexate (SELECT-COMPARE). ClinicalTrials.gov identifier: NCT02629159. Accessed November 8, 2022. A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov. Available at: . Accessed on November 8, 2022. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy. ClinicalTrials.gov. Available at: . Accessed on November 8, 2022. A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov. Available at: . Accessed on November 8, 2022. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. Available at: . Accessed on November 8, 2022. A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (Heads Up). ClinicalTrials.gov. Available at: . Accessed on November 8, 2022. Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-TAK). ClinicalTrials.gov. Available at . Accessed on November 8, 2022. A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2). ClinicalTrials.gov. Available at: . Accessed on November 8, 2022. SKYRIZI® (risankizumab) [Package Insert]. North Chicago, Ill.: AbbVie Inc. SOURCE AbbVie